Allylamine

Allylamine

SCHEMBL27612901

C=CCN.c1ccc2c(c1)OCCO2

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 1/20 0.61
ICAM1 P05362 1/20 0.61
ITGAL P20701 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.54
LMNA P02545 3/20 0.54
CRHBP P24387 2/20 0.54
CRHR2 Q13324 2/20 0.54
HTT P42858 2/20 0.54
ABCG2 Q9UNQ0 1/20 0.42
MAPT P10636 3/20 0.40
ALDH1A1 P00352 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 2/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 2/20 0.40
MAOA P21397 2/20 0.37
MAOB P27338 2/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
SLC6A2 P23975 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Allylamine SCHEMBL11849659 0.80 CTNNB1 (0.40) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL27796077 0.78 ITGB2 (1.00) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL11519392 0.78 ITGB2 (1.00) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL6791411 0.78 ITGB2 (1.00) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL11406989 0.78 ITGB2 (1.00) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL8518 0.78 ITGB2 (1.00) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL29997436 0.78 ITGB2 (1.00) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL11399163 0.78 ITGB2 (1.00) ITGB2ICAM1ITGALSMN1; SMN2LMNA
Formaldehyde SCHEMBL27608187 0.76 ITGB2 (0.82) ITGB2ICAM1ITGALSMN1; SMN2LMNA
Methylamine SCHEMBL3886898 0.76 ITGB2 (0.82) ITGB2ICAM1ITGALSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1678321-A Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS INC (US) 2005-10-05 CN disclosed